Asbestosis

Summary

Asbestosis (MONDO:0016466) is a disease and 7 clinical trials. Top therapeutic interventions include pirfenidone and xenon xe-129, hyperpolarized. A subtype of pneumoconiosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]
• Phenotypes (HPO): 35
• Clinical trials: 7

Clinical features

Signs & symptoms

Clinical features (HPO)

35 HPO clinical features (Orphanet curated; top 35 by frequency):

HPO ID	Term	Frequency
HP:0002086	Abnormality of the respiratory system	Frequent (30-79%)
HP:0002091	Restrictive ventilatory defect	Frequent (30-79%)
HP:0002094	Dyspnea	Frequent (30-79%)
HP:0002207	Diffuse reticular or finely nodular infiltrations	Frequent (30-79%)
HP:0002792	Reduced vital capacity	Frequent (30-79%)
HP:0002875	Exertional dyspnea	Frequent (30-79%)
HP:0003546	Exercise intolerance	Frequent (30-79%)
HP:0006530	Abnormal pulmonary interstitial morphology	Frequent (30-79%)
HP:0030874	Oxygen desaturation on exertion	Frequent (30-79%)
HP:0031246	Nonproductive cough	Frequent (30-79%)
HP:0031631	Subpleural honeycombing	Frequent (30-79%)
HP:0031944	Pleural thickening	Frequent (30-79%)
HP:0031998	Late inspiratory crackles	Frequent (30-79%)
HP:0032341	Reduced forced vital capacity	Frequent (30-79%)
HP:0045051	Decreased DLCO	Frequent (30-79%)
HP:0000961	Cyanosis	Occasional (5-29%)
HP:0001648	Cor pulmonale	Occasional (5-29%)
HP:0001708	Right ventricular failure	Occasional (5-29%)
HP:0002206	Pulmonary fibrosis	Occasional (5-29%)
HP:0002878	Respiratory failure	Occasional (5-29%)
HP:0012418	Hypoxemia	Occasional (5-29%)
HP:0025179	Ground-glass opacification on pulmonary HRCT	Occasional (5-29%)
HP:0030828	Wheezing	Occasional (5-29%)
HP:0030849	Hepatojugular reflux	Occasional (5-29%)
HP:0030879	Interlobular septal thickening on pulmonary HRCT	Occasional (5-29%)
HP:0031352	Chest tightness	Occasional (5-29%)
HP:0032016	Abnormal sputum	Occasional (5-29%)
HP:0100749	Chest pain	Occasional (5-29%)
HP:0100759	Clubbing of fingers	Occasional (5-29%)
HP:0000969	Edema	Very rare (<1-4%)
HP:0001685	Myocardial fibrosis	Very rare (<1-4%)
HP:0030078	Lung adenocarcinoma	Very rare (<1-4%)
HP:0100001	Malignant mesothelioma	Very rare (<1-4%)
HP:0100721	Mediastinal lymphadenopathy	Very rare (<1-4%)
HP:0100750	Atelectasis	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	asbestosis
Mondo ID	MONDO:0016466
EFO	EFO:0007153
MeSH	D001195
Orphanet	2302
DOID	DOID:10320
ICD-11	898495881
NCIT	C84573
SNOMED CT	22607003
UMLS	C0003949
MedGen	2462
GARD	0005852
Is cancer (heuristic)	no

Also known as: asbestos dust pneumoconiosis · asbestos pneumoconiosis · asbestosis · idiopathic interstitial pneumonitis - from asbestos exposure · pneumoconiosis from asbestos dust · pulmonary fibrosis - from asbestos exposure

Disease family

This is a subtype of pneumoconiosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › pneumoconiosis › asbestosis

Related subtypes (13): mixed mineral dust pneumoconiosis, baritosis, pneumoconiosis due to talc, slate pneumoconiosis, Caplan syndrome, silicosis, anthracosilicosis, anthracosis, byssinosis, pulmonary hemosiderosis, chronic beryllium disease, mixed dust pneumoconiosis, graphite pneumoconiosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04161014	PHASE2	UNKNOWN	The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial
NCT02748798	EARLY_PHASE1	TERMINATED	Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
NCT04016181	Not specified	ENROLLING_BY_INVITATION	The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study
NCT00005280	Not specified	COMPLETED	Specialized Center of Research in Occupational and Immunologic Lung Disease
NCT02280343	Not specified	UNKNOWN	Oscillation Mechanics of the Respiratory System Asbestos Exposed: Early Diagnosis
NCT04473742	Not specified	COMPLETED	Effects of Silica and Asbestos Fibres on the Efferocytosis Capacities of Macrophages
NCT05133453	Not specified	UNKNOWN	Pirfenidone Use in Asbestosis Patients: Efficacy and Prognosis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PIRFENIDONE	4	1
XENON XE-129, HYPERPOLARIZED	4	1